AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00216359
Drug: antiretroviral co-medication beside Fuzeon
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01062399
Drug: concurrent RAD001 10 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During radiation: RAD001 10 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
Trial: NCT01062399
Drug: concurrent RAD001 2.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During radiation: RAD001 2.5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
Trial: NCT01062399
Drug: concurrent RAD001 5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During radiation: RAD001 5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
Trial: NCT01062399
Drug: post-radiation RAD001 10 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
Trial: NCT01509586
Drug: Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PREP Group will be given a sample supply of a PREP product that is already on the market. It is unclear if it is safer than cigarettes, and that is why it is classified as a Potentially Reduced Exposure Product. It provides both nicotine and tobacco in the form of a pouch that can be thrown away after used. Unlike chewing tobacco, there is no need for spitting with this product. There are multiple flavors and participants will have his/her choice of preferred flavor. This group will be asked to sample the product and use it in several ways, but whether a participant uses the product or not is up him/her.
Trial: NCT01320579
Drug: Placebo for cis-UCA emulsion cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
Trial: NCT02389413
Drug: PQ912 oral
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02207530
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 monotherapy
Trial: NCT00536731
Drug: Symbicort Turbuhaler
RxNorm normalized name: Symbicort Turbuhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
Trial: NCT00536731
Drug: Symbicort pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
Trial: NCT00474630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00626795
Drug: TD1414 2% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID 7 days
Trial: NCT00626795
Drug: TD1414 2% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TID 7 days
Trial: NCT00626795
Drug: Bactroban® (mupirocin) 2% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID 7 days
Trial: NCT00856752
Drug: NRL972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
Trial: NCT00856752
Drug: NRL972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference test: Single intravenous administration of 2 mg NRL972
Trial: NCT00856752
Drug: NRL972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
Trial: NCT04385303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One intra-articular injection of 0 mg lorecivivint in 2 m vehicle
Trial: NCT00355589
Drug: Ramipril and hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05921916
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule solid microcrystalline cellulose
Trial: NCT03267329
Drug: Duowell®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%\~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%
Trial: NCT00052429
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02711670
Drug: chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03827577
Drug: Standard medical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.
Trial: NCT04239560
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During each radiotherapy session, 15 minutes before radiotherapy, the Placebo gel which be free of any chemical used and patients followed up.
Trial: NCT01174394
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
Trial: NCT01671085
Drug: LY3015014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SQ
Trial: NCT01671085
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SQ
Trial: NCT00984659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo DISKUS twice a day for 8 weeks
Trial: NCT02432677
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
Trial: NCT02432677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
Trial: NCT01083290
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of one tablet; 25 mg tablet
Trial: NCT01083290
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of one tablet; 50 mg tablet
Trial: NCT01083290
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of one tablet; 100 mg tablet
Trial: NCT03476018
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
Trial: NCT02183545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given as tablet (matching placebo of BI 1060469)
Trial: NCT02052960
Drug: CetuGEX™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration
Trial: NCT02052960
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
Trial: NCT01241513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01615003
Drug: Xuesaitong soft capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
Trial: NCT01615003
Drug: Xuesaitong soft capsule Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
Trial: NCT02183298
Drug: BI 1356 BS - intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02225067
Drug: Calcium (13C)Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Visit 1 and Visit 2, 24-hour gastric pH monitoring and C13-CAC breath test containing 200 mg of Calcium (13C)Carbonate
Trial: NCT00722592
Drug: pegylated liposomal doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.
Trial: NCT01312350
Drug: neoadjuvant docetaxel/cisplatin/fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.
Trial: NCT01312350
Drug: No treatment before definitive CCRT
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43
Trial: NCT01022853
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral continuously
Trial: NCT00163553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00675285
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet 5 mg once/day for 4 weeks
Trial: NCT00287833
Drug: Bowman-Birk inhibitor concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT04172831
Drug: Placebo SL Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Trial: NCT04159519
Drug: Fasenra®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Benralizumab 30 mg/mL, 1 mL fill volume via subcutaneous injection every 4 weeks for first 3 doses (prior to study inclusion), every 8 weeks thereafter.
Trial: NCT00077584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
Trial: NCT04416776
Drug: Strabismus diagnostic system.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An AI platform based on corneal light-reflection photos to facilitate the diagnosis and angle evaluation of strabismus and to provide advice for surgical planning.
Trial: NCT00722540
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Trial: NCT00722540
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Trial: NCT00722540
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Trial: NCT00722540
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Trial: NCT00722540
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Trial: NCT03281226
Drug: RIPE (2m) and RI (4m)
RxNorm normalized name: Ri-Mag Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
Trial: NCT03281226
Drug: RIPE+NAC (2m) and RI (4m)
RxNorm normalized name: Ri-Mag Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
Trial: NCT03625219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
Trial: NCT02004652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin, 50mg, tablet.
Trial: NCT00088010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, tablet, once a day for 36 months
Trial: NCT01901133
Drug: MDV3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04341844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
Trial: NCT01544595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00509873
Drug: placebo eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Trial: NCT01417780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% sodium chloride) administered as a single IV infusion
Trial: NCT01059604
Drug: Sumatriptan-naproxen combination
RxNorm normalized name: naproxen / sumatriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan-naproxen combination
Trial: NCT01345786
Drug: Commercial NOMAC-E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods
Trial: NCT01345786
Drug: Phase 3 NOMAC-E2 Batch A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch A) orally in the morning on Day 1 for all periods
Trial: NCT02096939
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02532868
Drug: MK-0457
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00097422
Drug: OPT-80
RxNorm normalized name: Glau-Opt
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01666444
Drug: pegylated liposomal doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01666444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04150640
Drug: Nal-IRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy drug
Trial: NCT01993329
Drug: Placebo to mimic 50 mg tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic gefapixant 50 mg tablets
Trial: NCT03242928
Drug: AFQ056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg and 100 mg tablets taken orally
Trial: NCT03242928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets taken orally BID
Trial: NCT03251339
Drug: US-Neulasta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
Trial: NCT02461914
Drug: PEX168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200µg,injected subcutaneously,once a week.
Trial: NCT03567291
Drug: TEV-50717
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6, 9, and 12 mg oral tablets
Trial: NCT03567291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00915967
Drug: Placebo (Saline Solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
Trial: NCT04454996
Drug: Chang 'an II Recipe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
Trial: NCT04454996
Drug: The placebo of tong-jiang granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
Trial: NCT04454996
Drug: The placebo of Chang 'an II Recipe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
Trial: NCT00923273
Drug: FDG-PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET CT will be performed at baseline and after two cycles of treatment.
Trial: NCT01097616
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
Trial: NCT00003386
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01996319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once a day via Breezhaler® device
Trial: NCT00130208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg gelcap
Trial: NCT02405039
Drug: EBI-005
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day
Trial: NCT02405039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
Trial: NCT01505491
Drug: BI695501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 695501 single s.c injection
Trial: NCT03855306
Drug: Glibesyn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 5 mg Glibenclamide
Trial: NCT00658970
Drug: KX2-391
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops
Trial: NCT00282919
Drug: Azithromycin plus chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose of 2000 mg Azithromycin plus 600 mg chloroquine base
Trial: NCT04742517
Drug: ASP1128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT04742517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT00153634
Drug: IV amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-7.5 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
Trial: NCT00153634
Drug: PO azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg once daily
Trial: NCT04117919
Drug: paper mulberry leaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids+paper mulberry leaf The botanical origin of paper mulberry leaf is Broussonetia papyrifera (L.) Vent.
Trial: NCT04516759
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg film-coated tablets (at daily dose of 100mg BID)
Trial: NCT00153634
Drug: IV tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2.5-3.3 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site